Synthego Says It Doesn't Infringe Agilent CRISPR Patents
Genome engineering company Synthego Corp. wants a California federal court to find that its products relating to the breakthrough gene-editing technology CRISPR don't infringe a pair of Agilent Technologies Inc. patents....To view the full article, register now.
Already a subscriber? Click here to view full article